Next Gen Immuno-Oncology Virtual Congress (Time Zone - GREENWHICH MEAN TIME(GMT))

Next Gen Antibodies and Cellular Therapy

Opening remarks from the Chairman

Sophia Karagiannis, Ann White, ,

Keynote: PD-1 Antibodies are Transforming Cancer Care both as Mono- and Combination Therapy

Avidimabs, Fc engineering to enhanced the avidity of mabs

Lindy Durrant, Professor, Cancer Immunotherapy, University of Nottingham, UK

CAR T cell research solutions by Miltenyi Biotec

Marcello Stein , Global Product Manager, T Cell Immunology , Miltenyi Biotec, Germany

CAR T-cell immunotherapy of solid tumours: parallel learning from the clinic and lab

John Maher, Scientific Founder and Chief Scientific Officer, Leucid Bio

Monoclonal Antibodies and Cellular Therapy

Accelerating ImmunoOncology research with Human Primary Cells

Manish Kumar, Product Manager Cells and Media, PromoCell

IgE class antibodies for cancer treatment: activating the tumour microenvironment

Sophia Karagiannis, Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK

Networking and One-on-One Meetings on the event portal

In vitro T cell dysfunction / exhaustion-like assays for functional characterization and/or screening of immunomodulatory candidate drugs

Eden Kleiman , Senior Scientist Immuno-oncology, CrownBio

Development of the next generation immuno-modulators towards the clinic: A humanized anti-BTN3A antibody activating Vγ9Vδ2 T cells

Aude De Gassart , Director of Preclinical Research , ImCheck Therapeutics, France

A versatile Plug-and-Play platform, BiXAb, for development of bispecific antibodies with diverse set of mechanisms of action

Mustapha Faroudi , Director of Immuno Oncology, , Biomunex Pharmaceuticals

Selective T Cell Redirection (STR): The Art Triggering A Natural Yet Comprehensive Immune Response In Cold Tumors

Asher Nathan , CEO , NeoTX Therapeutics, Israel

Closing Remarks from Chairman

End of Day 1 and One-one-One Networking

Immune Checkpoint Inhibitors & Combination Strategies

Opening remarks from the Chairman

Ali Roghanian, Assistant Professor, Cancer Immunology, University of Southampton, UK

Keynote: ICI and chemotherapy, why and how?

Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene

Enhanced Biomarker Discovery and Validation Using TMT® Proteomics

Illip Burmester, Ph.D. , Scientific Sales Support Europe, Proteome Sciences

Using CRISPR screens in immune cells to better understand the tumour-immune interface

Nicola McCarthy , Global Scientific Liaison , Horizon Discovery, UK

Pre-clinical & Translational Immuno-Oncology Developments

Humanized Mouse Models for Immuno-Oncology Research

Bradlee Heckmann, CSO, Asha Therapeutics

Engineering humanized mouse models of haematological and solid malignancies

Ali Roghanian, Assistant Professor, Cancer Immunology, University of Southampton, UK

Networking and One-on-One Meetings on the event portal

Live Biotherapeutic MRx0518 induces broad anti-tumour immunity and demonstrates potential synergy with checkpoint inhibition

Marsilio Adriani, Principal Scientist, 4D Pharma

Enabling the expansive interrogation of a tumor and its microenvironment from a single sample for precision oncology biomarker discovery applications

Maik Pruess PhD, Senior Field Application Scientist , Personalis Inc

Accelerate Therapeutic Antibody and Viral Vectors Manufacturing Partnering with GenScript ProBio

Ben Xu, BD Director, Biologics Development, GenScript, USA

Strategies to enhance the efficacy of tumor antigen-specific CAR-based immunotherapy with solid tumors

Soldano Ferrone, Professor, Harvard University, USA

Integrin αvβ8-expressing tumor cells serve as a platform for TGF-β activation

Sam Shrivastava, Chief Executive Officer, Founder, Venn Therapeutics

Closing Remarks from Chairman

End of Day 1 and One-one-One Networking

Therapeutic Antibodies and Cellular Therapy

Opening remarks from the Chairman

Ann White, Senior Principal Scientist, UCB Celltech, UK

Advances in IO

Specificity profiling of T cell receptor (TCR)-based bispecifics

Stephen Harper , Group Leader, Protein Science, Immunocore, UK

Tumor-localized activation of the immune system using antibody-Anticalin® fusion proteins

Markus Zettl , Director, Immuno-Oncology, Pieris Pharmaceuticals, Germany

MHC-I/MAGE complexes as means for tumor-specific T cell retargeting

Renier Heijkants, Senior Scientist, APO-T

The Rising Challenges for Patents in Immuno-Oncology

Will Arends , Chartered (UK) and European Patent Attorney, Marks & Clerk, UK

Arming CAR T cells with Natural killer receptors

David Gilham, Vice President, R&D, Celyad, UK

Networking and One-on-One Meetings on the event portal

Panel Discussion: Opening & Introduction to PHC Group, IHC Microfluidics Solutions , Archiving solutions

Steven Lynum, Jennifer Freeland, Grace Robinson, ,

Pre-clinical development of Antibody Drug Conjugates for applications in gynaecological cancers (Skype Presentation)

Deyarina Gonzalez, Professor, Molecular Medicine , Swansea University Medical School, UK

Unraveling the complexity of the tumor microenvironment using multiplex immunofluorescence

Angela Vasaturo , Senior Field Application Scientist , Ultivue, UK

The dark side of IFN gamma – negative feedback regulation of tumour infiltrating T cells by IFN gamma restricts tumour immunity

Audrey Gerard, KTRR Senior Research Fellow , University of Oxford, UK

Closing Remarks from Chairman

End of Conference and One-one-One Networking

Immune Checkpoint Inhibitors and Combinations

Opening remarks from the Chairman

Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene

Personalized Immunotherapy, Vaccines and Oncolytic Viral Therapy

Invasive tumours and their immunosuppressive functions

Victoria Sanz-Moreno , Professor, Cancer Cell Biology , Cancer Research UK Barts Centre, UK

Mapping the Immune Landscape of High Risk Chemotherapy Resistant Breast Cancers

Sheeba Irshad, CRUK Clinician Scientist & Honorary Medical Oncologist, Guys Hospital, UK

Site-selective chemical reactions on proteins; towards homogenous bioconjugates as targeted therapeutics

Archie Wall , PhD Researcher , University College London, UK

Delivering Innovative Solutions for Immuno-oncology Drug Discovery

Justyna Rzepecka , Principal Scientist Immunology, Concept Lifesciences

The functional role of B cells within tertiary lymphoid structures in the human tumor microenvironment

Bruno Tullia, Assistant Professor, Immunology, University of Pittsburgh

Networking and One-on-One Meetings on the event portal

Attune NxT Acoustic Focusing Flow Cytometer: Efficient. Flexible. Transformative

Idhnan Hussain , Flow Cytometry Technical Specialist , Thermo Fischer Scientific, UK

From 2D to 3D imaging: How High Content Screening can take Immuno-Oncology research to the next level

James Watson , Senior Business Development Manager, Thermo Fischer Scientific, UK

Increasing the Targeting Specificity of Immunotherapeutics

Colin Self , CEO, Precision ImmunoTherapeutics

New opportunities for integrating Immune System Imaging in Clinical trials

Rorn Korn , Founder, Chief Medical Officer , Imaging Endpoints, USA

Closing Remarks from Chairman

End of Conference and One-one-One Networking